Mytolac (Lanreotide)

Lanreotide mimics the natural hormone somatostatin and binds to somatostatin receptors, mainly subtypes 2 and 5. This binding blocks adenylate cyclase, lowers cyclic AMP, and suppresses the release of growth hormone, insulin‑like growth factor‑1, and various gastrointestinal hormones, thereby reducing tumor activity and hormone‑driven effects.

The dose and frequency of Mytolac are individualized by the prescribing clinician based on the specific indication, disease severity, patient response, and any relevant comorbidities. The prescriber will decide the appropriate regimen and may adjust it over time according to clinical monitoring.

Safety data for lanreotide in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Mytolac, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Both lanreotide and octreotide belong to the somatostatin analogue class and share similar mechanisms. Lanreotide typically has a longer half‑life, allowing for less frequent dosing (often every 4 weeks) compared with octreotide, which may require daily or twice‑daily injections. Efficacy in controlling hormone levels is comparable, but the choice depends on patient preference, tolerability and clinical judgment.

Mytolac should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours and return it to refrigeration promptly.

Mytolac is given as a subcutaneous injection, usually into the abdomen or thigh. The healthcare professional prepares the dose using aseptic technique, selects an appropriate injection site, and administers the medication at a 45‑degree angle. Patients should be instructed on proper site rotation and disposal of used needles according to local regulations.

Serious adverse events, although uncommon, include gallbladder disease or gallstone formation, acute pancreatitis, and severe hypersensitivity reactions such as anaphylaxis. Patients should be monitored for abdominal pain, jaundice, or signs of allergic reaction, and the medication should be discontinued promptly if any of these events occur.

Mytolac is contraindicated in individuals with a known hypersensitivity to lanreotide or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, uncontrolled diabetes, or active gallbladder disease. The prescriber should evaluate each patient’s medical history before initiating therapy.